Institute for International Research

Special Discounted Hotel Rate

Special Discounted Hotel Rate Available Until May 31, 2010.
To book your room, call 1-800-228-9290 and mention that you are an IBC attendee at this event.

Keynote Presentations

Are There Drivers Left for Further Process Optimization in Cell Line Development?
Michael W. Glacken, Ph.D., Senior Director, Biologics Process Development, Millennium Pharmaceuticals

Beyond Just High Titers - The Future of Cell Line Engineering
Matthew S. Croughan, Ph.D., George B. and Joy Rathmann Professor and Director of the Amgen Bioprocessing Center, Keck Institute

Featured Presentations

Difficult-to-Express Proteins and Using Transient Expression to Predict Stable Cell Line Behavior
John Delaney, Ph.D., Director, Protein Sciences, Amgen Inc.

Strategies for Resolving Downstream Bottlenecks to Enable High Titer Recoveries
Chris Dowd, Ph.D., Principal Engineer, Senior Group Leader, Late Stage Purification, Genentech, Inc.

The Most Comprehensive Coverage to Help You Overcome the Next Wave of Challenges after Titer Increase and Optimize Cell Line Development

IBC's 6th Annual Cell Line Development and Engineering will deliver 37 presentations in a three-day, single-track format, making this event the most valuable and intensive learning experience you can attend.

This program has earned its reputation by attracting thought leaders in industry and academia to collectively examine and provide solutions to the industry's most daunting challenges. For 2010, we have developed an agenda to help you achieve the ultimate goal of improving quality and understanding of your cell lines while reducing time and cost of development.

By joining us, you will hear exclusive case studies and data-driven presentations from Abbott, Amgen, Bayer, Biogen Idec, Centocor, Genzyme, Genentech, GSK, Lonza, MedImmune, Millennium, Pfizer, Regeneron and more to help your company:

• Improve cell line stability and clone expression through vector redesign
• Increase speed of development with faster, more predictive screening techniques
• Integrate genomic techniques and technologies which have impacted cell line development
• Overcome timeline bottlenecks in development while improving quality and uniformity
• Incorporate manufacturability to deal with difficult-to-express proteins
• Apply DOE approaches to clone screening, media design and development
• Evaluate new mammalian and non-mammalian expression systems to determine if there are viable alternatives to CHO
• Generate cell lines capable of stable and scaleable expression of novel molecules

Request Information
Join the priority contact list for the latest updates and announcements on the 2010 program.